Bioactivity of Greek honey extracts on breast cancer (MCF-7), prostate cancer (PC-3) and endometrial cancer (Ishikawa) cells: Profile analysis of extracts

10590 Background: PARP inhibitors (e.g. Olaparib or niraparib) have been approved by FDA as a targeted therapy for many tumors harboring germline or somatic BRCA1/2 (g or sBRCA1/2), including ovarian cancer, prostate cancer, breast cancer and pancreases cancer. It is imperative to study the distribution of BRCA1/2 across cancer type. In this study, we aim to assess the landscape of BRCA1/2 alterations in solid tumors and evaluate the feasibility of circulating tumor DNA (ctDNA) tested by next-generation sequence (NGS) as a tool to detect BRCA1/2 alterations. Methods: For tissue specimen, genomic DNA from formalin fixed paraffin-embedded (FFPE) tumor specimens or fresh tumor tissues was used for sequence analysis. Genomic DNA (gDNA) from white blood cells was extracted using the QIAamp DNA Mini Kit (Qiagen). For ctDNA, cell-free DNA libraries were prepared using the KAPA Hyper Prep Kit following the manufacturer’s protocol. The captured libraries were loaded onto a NovaSeq 6000 platform (Illumina) for 100bp paired-end sequencing. The testing was performed in the College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) -certified 3D Medicines Library. Results: A total of 27, 835 patients were tested using tumor tissue during Jan. 1th 2017 to June 1th 2020, including 43% (N = 12089) of non-small cell lung cancer, 19% (N = 5357) of colorectal cancer, 8% (N = 2181) of liver cancer, 6% (N = 1621) of gastric cancer, 5% (N = 1479) of biliary tract cancer, 4% (N = 1084) of kidney cancer, 4% (N = 1045) of pancreas cancer, 3% (N = 689) of breast cancer and 2% (N = 599) of ovarian cancer. Across all tumor types, the known or likely deleterious BRCA1/2 alterations were identified in 2147 (7.7%) patients. Ovarian cancer had the highest frequency of BRCA1/2 alteration (23.4%), followed by endometrial cancer (12.7%) and breast cancer (10.6%). BRCA1/2 alteration was found in 8.8% prostate cancer and 4.2% pancreas cancer respectively. Across all tumor types, the known or likely deleterious gBRCA1/2 alterations were identified in 369 (1.3%) patients. Notably, ovarian cancer had the highest frequency of gBRCA1/2 alteration (13.9%), followed by breast cancer (7%), prostate cancer (4.4%) and endometrial cancer (4.1%). No clear hotspot mutations and mutated codons were spread throughout g or sBRCA1/2 mutations. Additionally, among 15699 patients who suffered ctDNA sequencing, any known or likely deleterious sBRCA1/2 alterations were identified in 358 (2%) patients. Similar to the results of tissue sequencing, ovarian cancer had the highest frequency of sBRCA1/2 alteration (16.67%), followed by endometrial cancer (9.68%), prostate cancer (7.18%) and breast cancer (5.58%) in the blood cohort. Conclusions: BRCA1/2 alterations existed across tumor types and the landscape of g or sBRCA1/2 alterations varied according to cancer type. Furthermore, ctDNA can be used as a potential tool to detect BRCA1/2 alterations.

Download Full-text

Hormone-related tumors in transsexuals receiving treatment with cross-sex hormones

Acta Endocrinologica ◽

10.1530/eje-08-0289 ◽

2008 ◽

Vol 159 (3) ◽

pp. 197-202 ◽

Cited By ~ 89

Author(s):

Andreas Mueller ◽

Louis Gooren

Keyword(s):

Breast Cancer ◽

Prostate Cancer ◽

Ovarian Cancer ◽

Endometrial Cancer ◽

Breast Carcinoma ◽

Sex Hormones ◽

Single Case ◽

Review Of The Literature ◽

Male To Female ◽

Estrogen Administration

ObjectiveTo assess the risk of development of hormone-related tumors in transsexuals receiving treatment with cross-sex hormones.DesignDescription of cases of transsexuals who have developed a hormone-related malignancy observed in their own clinic or reported in the literature. Recommendations for early diagnosis and prevention are presented.MethodsReview of the literature in PubMed.ResultsIn male-to-female transsexuals receiving estrogen administration, lactotroph adenomas, breast cancer, and prostate cancer have been reported. In female-to-male transsexuals receiving treatment with testosterone, a single case of breast carcinoma and several cases of ovarian cancer have been reported. So far endometrial cancer has not been encountered though it remains a potential malignant development.ConclusionsThere are so far only a few cases of hormone-related cancer in transsexuals. There may be an underreporting. The probability of a hormone-related tumor increases with the duration of exposure to cross-sex hormones and the aging of the population of transsexuals.

Download Full-text

ATRA-hydrazonate derivatives and their copper complexes against hormone-dependent (MCF-7), hormone-independent (MDA-MB-231and BT-20) breast cancer and androgen-independent (PC3) prostate cancer cell lines

Inorganic Chemistry Communications ◽

10.1016/j.inoche.2012.05.027 ◽

2012 ◽

Vol 23 ◽

pp. 17-20 ◽

Cited By ~ 4

Author(s):

Alok Vyas ◽

Sommai Patitungkho ◽

Abeda Jamadar ◽

Shreelekha Adsule ◽

Subhash Padhye ◽

...

Keyword(s):

Breast Cancer ◽

Prostate Cancer ◽

Cell Lines ◽

Cancer Cell ◽

Copper Complexes ◽

Prostate Cancer Cell ◽

Cancer Cell Lines ◽

Prostate Cancer Cell Lines ◽

Androgen Independent ◽

Mcf 7

Download Full-text

Novel dermacozine-1-carboxamides as promising anticancer agents with tubulin polymerization inhibitory activity

RSC Advances ◽

10.1039/c9ra02416f ◽

2019 ◽

Vol 9 (32) ◽

pp. 18670-18677 ◽

Cited By ~ 2

Author(s):

Venkata Rao Ghanta ◽

Nagaraju Madala ◽

Aparna Pasula ◽

Sai Kiran S. S. Pindiprolu ◽

Kumara Swamy Battula ◽

...

Keyword(s):

Breast Cancer ◽

Prostate Cancer ◽

Lung Cancer ◽

Cytotoxic Activity ◽

Cell Lines ◽

Anticancer Agents ◽

Inhibitory Activity ◽

Tubulin Polymerization ◽

Mcf 7

In the present study, novel dermacozine-1-carboxamides (8a–8n) were synthesized and screened for their in vitro cytotoxic activity against three different cancer cell lines: MCF-7 (breast cancer), A-549 (lung cancer) and DU145 (prostate cancer).

Download Full-text

Novel Tocopherol Succinate-Polyoxomolybdate Bioconjugate as Potential Anti-Cancer Agent

10.21203/rs.3.rs-214396/v1 ◽

2021 ◽

Author(s):

Mahnaz Sadat Hosseini ◽

Shaghayegh Haghjooy Javanmard ◽

nasim Dana ◽

Laleh Rafiei ◽

Mahboubeh Rostami

Keyword(s):

Breast Cancer ◽

Prostate Cancer ◽

Flow Cytometry ◽

Endothelial Cell ◽

Cancer Cell ◽

Prostate Cancer Cell ◽

Umbilical Vein ◽

Cancer Cell Line ◽

Anti Cancer ◽

Mcf 7

Abstract Up to now, polyoxometalates (POMs) have shown encouraging anti-tumor activities. Unfortunately, the general toxicity with a fateful characteristic has prevented their further clinical application as inorganic drugs. In this study, we synthesized tocopherol succinate-polyoxomolybdate conjugate (T2POMo) as a new organic-inorganic hybrid and evaluated its characteristic in-vitro to introduce a safer and more potent POM derivative in the scope of cancer treatment. We synthesized the hybrid via a simple amidation reaction between POMo and tocopherol succinate (TS) using the carbodiimide strategy. The structure was approved by FTIR and HNMR spectroscopy besides the other techniques. The anti-cancer activity was studied on breast cancer cell (MCF-7) and prostate cancer cell (LNCAP) using MTT method and normal cell non-toxicity was checked on Human umbilical vein endothelial cell (HUVEC) using the same protocol, and the flow cytometry technique was used to investigate the apoptosis. The cytotoxicity studies on the breast cancer cell line (MCF-7), prostate cancer cell line (LNCAP) and human umbilical vein endothelial cell (HUVEC) showed that the presence of tocopherol succinate could change and modulate the potency of the final hybrid (IC50 of 167.3 mg/mL on MCF-7 & 234.1 mg/mL on LNCap respectivley). The results showed more cytotoxicity compared to the parent POMo for T2POMo conjugation on cancerous cells besides no significant cytotoxicity on normal cells. The flow cytometry results showed that the hybrid conjugation could result in a significant increase in apoptosis (60.88%). So tocopherol succinate bioconjugate of POMo as a novel and potent bioactive POMo could be a promising candidate for further pre-clinical assessments.

Download Full-text

Enantiomerically Pure [1, 2-Diamino-1-(4-fluorophenyl)butane]platinum(II) Complexes: Synthesis and Antitumor Activity against MCF-7 and MDA-MB 231 Breast Cancer and LnCaP/FGC Prostate Cancer Cell Lines

Archiv der Pharmazie ◽

10.1002/ardp.200400621 ◽

2004 ◽

Vol 337 (12) ◽

pp. 654-667 ◽

Cited By ~ 15

Author(s):

Anja Dullin ◽

Francois Dufrasne ◽

Michael Gelbcke ◽

Ronald Gust

Keyword(s):

Breast Cancer ◽

Prostate Cancer ◽

Antitumor Activity ◽

Cell Lines ◽

Cancer Cell ◽

Prostate Cancer Cell ◽

Cancer Cell Lines ◽

Prostate Cancer Cell Lines ◽

Enantiomerically Pure ◽

Mcf 7

Download Full-text

Heterogeneous Nuclear Ribonucleoprotein K Is Involved in the Estrogen-Signaling Pathway

Journal of the Endocrine Society ◽

10.1210/jendso/bvab048.2088 ◽

2021 ◽

Vol 5 (Supplement_1) ◽

pp. A1020-A1021

Author(s):

Erina Iwabuchi ◽

Yasuhiro Miki ◽

Kiyoshi Ito ◽

Takanori Ishida ◽

Hironobu Sasano

Keyword(s):

Breast Cancer ◽

Endometrial Cancer ◽

Cancer Patients ◽

Signaling Pathway ◽

Estrogen Signaling ◽

Ki 67 ◽

Heterogeneous Nuclear Ribonucleoprotein ◽

Nuclear Ribonucleoprotein ◽

Mcf 7 ◽

Positive Breast Cancer

Abstract Heterogeneous nuclear ribonucleoprotein K (hnRNPK) has been found in the nucleus, cytoplasm, and mitochondria. It is implicated in chromatin remodeling, transcription, splicing, and translation processes. Although hnRNPK has reportedly been associated with poor prognosis in colon cancer patients, it is beneficial in gastric cancer as it inhibits cancer cell proliferation. Expression of hnRNPK in ER (Estrogen receptor) -positive/PR (Progesterone receptor) -positive breast cancer was higher than other subtypes; however, the biological functions of hnRNPK in the ER-mediated signaling pathway have not been identified. In this study, we investigated the functions of hnRNPK in the estrogen-signaling pathway. We initially evaluated hnRNPK expression upon treatment with estradiol (E2) and ICI 182,780 in ERα-positive breast cancer cell line MCF-7. This initial evaluation revealed that expression of hnRNPK was increased by E2 treatment but decreased by ICI 182,780 treatment. We further evaluated the effects of estrogen-signaling pathway in hnRNPK knockdown MCF-7 cells using siRNA, which revealed that hnRNPK knockdown decreased ERα expressions and ERα target gene TFF1 by E2 treatment. In addition, we examined the interaction between hnRNPK and ERα because hnRNPK has been reported to interact with several other proteins. These interactions were detected using immunoprecipitation and proximity ligation assay. We then immunolocalized hnRNPK in breast cancer and endometrial cancer. hnRNPK expression was significantly higher in ERα-positive cancer cells in both breast and endometrial cancers. In contrast, hnRNPK expression was significantly lower in Ki-67-positive breast cancer while being significantly higher in Ki-67-positive endometrial cancer. hnRNPK has been found to function differently, depending on the type of cancer (breast or endometrial) that it is expressed in. However, further studies are required to clarify the clinical significance of hnRNPK in breast and endometrial cancer patients.

Download Full-text

The Effects of Progestogens on a Human Endometrial Cancer Cell Line Ishikawa and a Human Breast Cancer Cell Line MCF-7

Folia Endocrinologica Japonica ◽

10.1507/endocrine1927.61.3_220 ◽

1985 ◽

Vol 61 (3) ◽

pp. 220-227 ◽

Cited By ~ 1

Author(s):

Noboru YOSHIZUMI ◽

Ken SATOH ◽

Iwao NISHIYA

Keyword(s):

Breast Cancer ◽

Endometrial Cancer ◽

Cell Line ◽

Cancer Cell ◽

Human Breast Cancer ◽

Cancer Cell Line ◽

Human Breast Cancer Cell ◽

Human Breast ◽

Endometrial Cancer Cell ◽

Mcf 7

Download Full-text

Dietary Vitamin D3 and 1,25-Dihydroxyvitamin D3 (Calcitriol) Exhibit Equivalent Anticancer Activity in Mouse Xenograft Models of Breast and Prostate Cancer

Endocrinology ◽

10.1210/en.2011-1600 ◽

2012 ◽

Vol 153 (6) ◽

pp. 2576-2587 ◽

Cited By ~ 102

Author(s):

Srilatha Swami ◽

Aruna V. Krishnan ◽

Jennifer Y. Wang ◽

Kristin Jensen ◽

Ronald Horst ◽

...

Keyword(s):

Breast Cancer ◽

Prostate Cancer ◽

Serum Calcium ◽

Vitamin D3 ◽

The Body ◽

Dietary Vitamin ◽

Dihydroxyvitamin D3 ◽

1,25 Dihydroxyvitamin D3 ◽

Estrogen Synthesis ◽

Mcf 7

1,25-dihydroxyvitamin D3 [1,25(OH)2D3 or calcitriol], the hormonally active vitamin D metabolite, exhibits anticancer actions in models of breast cancer and prostate cancer. Because CYP27B1 (1α-hydroxylase), the enzyme catalyzing 1,25(OH)2D3 formation in the kidney, is also expressed in extrarenal tissues, we hypothesize that dietary vitamin D3 will be converted to 25(OH)D3 in the body and then to 1,25(OH)2D3 locally in the cancer microenvironment in which it will exert autocrine/paracrine anticancer actions. Immunocompromised mice bearing MCF-7 breast cancer xenografts showed significant tumor shrinkage (>50%) after ingestion of a vitamin D3-supplemented diet (5000 IU/kg) compared with a control diet (1000 IU/kg). Dietary vitamin D3 inhibition of tumor growth was equivalent to administered calcitriol (0.025, 0.05, or 0.1 μg/mouse, three times a week). Both treatments equivalently inhibited PC-3 prostate cancer xenograft growth but to a lesser extent than the MCF-7 tumors. Calcitriol at 0.05 μg and 0.1 μg caused modest but statistically significant increases in serum calcium levels indicating that the dietary vitamin D3 comparison was to a maximally safe calcitriol dose. Dietary vitamin D3 did not increase serum calcium, demonstrating its safety at the concentration tested. The vitamin D3 diet raised circulating 1,25 dihydroxyvitamin D levels and did not alter CYP27B1 mRNA in the kidney but increased it in the tumors, suggesting that extrarenal sources including the tumors contributed to the elevated circulating 1,25 dihydroxyvitamin D3. Both calcitriol and dietary vitamin D3 were equipotent in suppressing estrogen synthesis and signaling and other proinflammatory and growth signaling pathways. These preclinical data demonstrate the potential utility of dietary vitamin D3 supplementation in cancer prevention and therapy.

Download Full-text